Group study of UFT following instillation of anticancer drug for superficial bladder cancer

INTERVENTION: Treatment arm: Administration of oral UFT 400mg/day for 2 years Control arm: No treatment CONDITION: Non‐muscle Invasive Bladder Cancer PRIMARY OUTCOME: 3 year recurrence‐free survival INCLUSION CRITERIA: 1)Pathologically‐proven non‐muscle invasive bladder cancer after TUR‐Bt with diagnosis of UC, Ta or T1, G1 or G2. Only primary cases are eligible. 2)Treated with immediate instillation of THP (20mg in 20ml saline) after TUR‐Bt 3)20‐79 year old 4)ECOG Performance Status of 0 or 1 5)Tolerable to oral UFT 6)Life expectancy of > 3 years 7)Reserved organ function 8)Patients who can start protocol therapy within 4 weeks after TUR‐Bt 9)Written informed consent